Macaque Core -Core B

猕猴核心-核心B

• 批准号: 9023412
• 负责人: Vijayakumar Velu
• 金额: $ 96.07万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9023412
• 关键词: AIDS vaccine development; Adjuvant; Age; Alleles; Animals; Autopsy; Biopsy; Blood; Bone Marrow; Breeding; Caring; Cellular Immunity; Clinical; Clinical Chemistry; Collaborations; Collection; Communication; Control Animal; DNA; Dendritic Cells; Development; Diagnostic; Ensure; Evaluation; Gender; Genes; Genetic; Goals; HIV; HIV vaccine; HIV-1; Health Priorities; Hematology; Histologic; Human; Humoral Immunities; Immune; Immune response; Immunity; In Vitro; Infection; Infection prevention; Laboratories; Macaca; Macaca mulatta; Measures; Modified Vaccinia Virus Ankara; Monitor; Morbidity - disease rate; Mosses; Phase; Physical Examination; Research; Research Personnel; SIV; SIV Vaccines; Safety; Services; Simian T-lymphotropic virus 1; Specific qualifier value; Specimen; Surface; Swab; TNFSF5 gene; Testing; Tissue Sample; Universities; Vaccination; Vaccines; Viral; Virus; animal care; environmental enrichment for laboratory animals; global health; immunogenicity; lymph nodes; male; mortality; nonhuman primate; novel; novel strategies; physical conditioning; pre-clinical; programs; rectal; research clinical testing; response; sample collection; simian human immunodeficiency virus; success; tissue processing; vaccination strategy; vaccine efficacy; vector; vector vaccine

Human immunodeficiency virus (HIV)-1 infection is a leading cause of morbidity and mortality around the world, with many new infections occurring daily and the development of a safe and effective HIV vaccine is a critically important global health priority. An effective vaccine for HIV remains elusive and the development of an effective vaccine against HIV is the long-term solution to this problem. The success of the RV144 Thai HIV-1 efficacy trail showing 31 % of efficacy has given hope that indeed a protective HIV vaccine can be developed. The goal of this program is to generate novel vaccination approaches that enhance the quantity as well as quality of anti-viral cellular and humoral responses using CD40L as an adjuvant and MVA delta4 as a boosting vector. The overall objectives for this Core are to provide the required experimental animals and support services needed to facilitate the AIDS vaccine development studies proposed in projects 2 and 3. This will be accomplished by the following specific aims: 1. To select and provide male rhesus macaques from the Yerkes breeding colony suitable for the research aims of the macaque trials of the program project. 2. To provide exceptional animal care, veterinary care, and environmental enrichment. 3. To perform vaccine administrations to measure immunogenicity. 4. To perform sample collections including the collection of various tissue samples and secretions for in vitro studies. 5. To perform repeated rectal SHIV challenges on immunized and unimmunized control animals to test vaccine efficacy. 6. To perform periodic physical examinations and blood collections from the experimental animals. 7. To perform complete gross and histologic evaluation of any experimental animals that dies or sacrificed during the course of the study.

人类免疫缺陷病毒（HIV）-1感染是世界各地发病率和死亡率的主要原因。 世界上每天都有许多新的感染病例发生，开发安全有效的艾滋病毒疫苗是一项艰巨的任务。 这是一个至关重要的全球卫生优先事项。有效的艾滋病毒疫苗仍然难以捉摸， 有效的艾滋病毒疫苗是解决这一问题的长期办法。RV 144 Thai的成功 HIV-1有效性试验显示31%的有效性，这给人们带来了希望，即确实可以使用保护性HIV疫苗。 开发该计划的目标是产生新的疫苗接种方法， 以及使用CD 40 L作为佐剂和MVA δ 4的抗病毒细胞和体液应答的质量 作为一个助推器本核心的总体目标是提供所需的实验动物 及支援服务，以促进项目2及 3.这将通过以下具体目标来实现： 1.从Yerkes繁殖群中选择并提供适合研究的雄性恒河猴 猕猴试验项目的目的。 2.提供特殊的动物护理，兽医护理和环境丰富。 3.进行疫苗接种以测量免疫原性。 4.进行样本采集，包括采集各种组织样本和分泌物，用于 体外研究。 5.对免疫和未免疫对照动物进行重复直肠SHIV攻毒，以检测 疫苗效力 6.对实验动物进行定期体格检查和采血。 7.对死亡或处死的任何实验动物进行完整的大体和组织学评价 在研究过程中。